October 26, 2026
Oral Minoxidil vs. Oral Dutasteride: What Does the Newest Comparison Actually Show?
Why this question keeps coming up
If you have been researching hair loss for more than a week, you have seen the argument. One camp says oral dutasteride is the strongest option because it blocks more DHT than finasteride. Another says low-dose oral minoxidil is the underrated winner because it works through a different mechanism and is cheap. Most of the confident claims online come from individual experience, not head-to-head data. So a recent head-to-head study is worth reading closely, including its limits
.
What the study did
Researchers at the University of Guadalajara enrolled 67 men with androgenetic alopecia in an open-label trial published in Frontiers in Medicine in February 2026. Treatment was chosen by clinical judgment and shared decision-making rather than randomization. The four groups were oral dutasteride 0.5 mg daily, and oral minoxidil at 5 mg, 2.5 mg and 1 mg daily. Patients were assessed at baseline, three months and six months, and 46 of the 67 completed all six months.
What it found
Severity scores moved for minoxidil, not for dutasteride
On the clinical Hamilton-Norwood severity scale, all three minoxidil groups improved over six months. The dutasteride group did not change significantly. That is the headline some people will quote, and it is the finding most in need of context.
Total hair density did not significantly rise in any group
Using trichoscopy, no group showed a statistically significant increase in total hair density. In the dutasteride group, the proportion of thicker hairs rose in one scalp region and thin hairs fell. The 1 mg minoxidil group actually showed a small decline in temporal density. Differences between groups were mostly not statistically significant.
Why you should not read this as "minoxidil beats dutasteride"
The authors are open about the limits, and they matter:
The study was not randomized. Doctors and patients chose the treatment, so the groups may differ in ways that were not measured.
Each group had only 14 to 19 men, which is too small to detect modest differences reliably.
Six months is short. Medications that reduce DHT mainly slow loss and often show their value over a year or more, while a drug that prolongs growth can show earlier effects. A six-month window may favor one mechanism over the other.
Nearly a third of enrolled men did not complete the study.
The hair counts came from automated image analysis, and severity staging is partly subjective.
In other words, this is a useful signal and a reason to keep an open mind, not a verdict. A broader network meta-analysis of randomized trials of minoxidil combinations is a better place to look for how minoxidil performs alongside other treatments, though it too has its own limits on comparability.
How to think about the choice
Hair loss treatment is rarely either-or. The two drugs act on different parts of the problem. A 5-alpha-reductase inhibitor such as dutasteride or finasteride reduces the DHT signal that miniaturizes follicles. Minoxidil acts on the follicle through a separate pathway and is generally thought to prolong the growth phase. Many dermatologists and hair restoration physicians combine them, which is also why one drug failing to move a score in a short study does not make it useless as part of a plan.
A few practical questions are more useful than asking which pill wins:
What is your pattern and stage? Early thinning at the crown and a receding hairline at an advanced stage call for different expectations.
What side effects matter to you? Oral minoxidil can cause fluid retention, a faster heart rate, low blood pressure symptoms and unwanted facial or body hair growth. Dutasteride and finasteride carry their own sexual and mood-related warnings. These are reasons to take either one under a physician's guidance and with baseline health in mind, particularly if you have heart or blood pressure conditions.
How long can you realistically run the trial? Most treatments need at least six to twelve months before a fair judgment, and stopping usually means losing the benefit.
Are you planning a hair transplant? Medication that protects the hair you still have is often a core part of keeping a surgical result looking natural over time.
Where the evidence is heading
Newer approaches are in development, including topical agents such as PP405, which in an early phase 2a trial sponsored by its maker showed hair density gains in a subset of men with more advanced loss over a short window. That is exploratory and not a reason to delay proven treatment, but it shows why the field is moving and why current evidence is worth reading with a critical eye.
Bottom line
The newest head-to-head data on oral dutasteride and oral minoxidil is interesting and incomplete. It does not show that one clearly outperforms the other, and it does not show that either fails. If you are weighing these medications, have a physician examine your scalp, review your health history and set a measurable plan, with photos at consistent intervals so that you are judging results by evidence rather than by feel.
About HRIMN
If you want an in-person opinion on medical therapy, or on whether a transplant or a regenerative option fits you, the team at the Hair Restoration Institute of Minnesota offers a free consultation at www.HRIMN.com.
